New Study: Inflammation Already Elevated at the Earliest Stage of Heart-Kidney-Metabolic Syndrome

For years, clinicians focused on inflammation as a feature of established cardiovascular or metabolic disease. By the time someone had been diagnosed with diabetes, chronic kidney disease, or heart failure, elevated C-reactive protein was expected. What was less clear was whether inflammation was already elevated in the quiet early period, before any organ damage had registered on standard clinical tests. A study published in September 2026 in the European Journal of Preventive Cardiology offers a compelling answer, and the implications extend well beyond cardiology wards.

What the New Study Found

The research team analyzed data from 4,315 adults in the 2015 to 2018 National Health and Nutrition Examination Survey (NHANES), a nationally representative sample of the US population, to see how hs-CRP changed across the four stages of CKM syndrome. Using survey-weighted methods to ensure the results reflect the broader US population, the authors published their findings in a paper titled "High-sensitivity C-reactive protein across the cardiovascular-kidney-metabolic syndrome spectrum: a nationally representative, survey-weighted analysis of US adults" in the European Journal of Preventive Cardiology (Corsi et al., 2026). The study was also presented at the European Society of Cardiology Congress 2026.

The headline finding was the jump from stage 0 to stage 1. Average hs-CRP nearly doubled across that transition, which was the single largest change seen across any stage boundary in the entire spectrum. Crucially, this jump pushed average levels above 2 mg/L, the commonly used threshold that clinicians associate with elevated cardiovascular risk. From stage 1 onward, levels stayed above that threshold and continued to rise, but the steepest climb was already done at the very first step in the progression. The authors described this as evidence that chronic inflammation is established before organ damage begins, not as a response to it.

The implications of a cross-sectional design are worth understanding. Because the study measured CRP and CKM stage at a single point in time, it shows an association between the two rather than proving that inflammation drives CKM progression. The researchers acknowledged this and called for prospective studies to determine whether early hs-CRP predicts future progression. That is an important caveat, but it does not diminish the finding: across thousands of adults drawn to represent the entire US population, elevated inflammation and early CKM staging go together consistently.

What CKM Syndrome Actually Is

Understanding why this study matters requires understanding what CKM syndrome is and why cardiologists treat it as a framework rather than a single disease. In 2023, the American Heart Association published a presidential advisory in Circulation introducing the CKM concept as a way to unify how clinicians think about the connected risks of metabolic dysfunction, kidney disease, and cardiovascular disease (Ndumele et al., 2023). The advisory described four stages:

• Stage 0: No risk factors. Normal body weight, normal blood glucose and kidney function, no cardiovascular disease.
• Stage 1: Excess body weight or abdominal obesity, or mildly elevated blood sugar. No kidney disease, no cardiovascular disease.
• Stage 2: Metabolic risk factors plus chronic kidney disease or higher-risk metabolic conditions such as hypertriglyceridemia or diabetes.
• Stage 3: Subclinical cardiovascular disease, or very high calculated cardiovascular risk, in someone with stage 2 factors.
• Stage 4: Established cardiovascular disease, with or without kidney or metabolic comorbidity.

The framework was designed precisely to capture the continuum, acknowledging that the conditions do not arise independently. Visceral fat drives insulin resistance, which impairs kidney function, which raises blood pressure, which accelerates atherosclerosis. The AHA advisory emphasized that prevention efforts have historically waited too long, intervening only after cardiovascular disease had developed, when much of the organ damage was already done. The new hs-CRP study fits directly into this conversation: if inflammation is running high at stage 1, the prevention window opened even earlier than stage 2.

Why CRP Is the Biomarker That Makes This Story Possible

High-sensitivity CRP occupies a unique position in cardiovascular medicine because it is both a downstream readout of inflammatory activity and a well-validated signal of cardiovascular risk in its own right. The liver produces CRP in response to inflammatory cytokines, particularly interleukin-6, and the high-sensitivity assay can detect concentrations as low as 0.3 mg/L. Because metabolic dysfunction generates sustained low-grade inflammation rather than the sharp spikes seen in infection or injury, CRP measured with a high-sensitivity assay captures exactly the chronic, smoldering signal that the CKM framework is concerned with.

The 2 mg/L threshold has been part of cardiovascular risk discussions for two decades. Research from large prospective trials established that adults with hs-CRP above this level face meaningfully higher cardiovascular event rates than those below it, independent of cholesterol levels. The fact that the new NHANES analysis found average hs-CRP crossing this threshold already at CKM stage 1 is not a coincidence. It suggests that the metabolic disruptions driving early CKM, excess adiposity and impaired glucose regulation, are already producing enough inflammatory signaling to push CRP above the threshold linked to long-term risk.

The mechanism connecting early-stage metabolic dysfunction to elevated CRP runs primarily through adipose tissue. Excess visceral fat is not metabolically inert. It secretes pro-inflammatory cytokines including tumor necrosis factor-alpha and interleukin-6, which reach the liver and stimulate CRP production. This is why CRP tends to correlate with waist circumference and body fat distribution even in people who would not yet meet criteria for any disease diagnosis. The new study, by showing that this effect is already detectable at the population level in CKM stage 1, adds another data point to what is by now a well-established mechanistic story.

Supporting Evidence From 2026 Research

The new study does not stand alone. A separate 2026 analysis published in Mediators of Inflammation analyzed three nationally representative cohorts from the US, UK, and China, comprising over 200,000 adults, to find which of 15 circulating inflammatory markers best predicted CKM severity and future progression (Zeng et al., 2026). Using machine learning approaches, the authors identified a composite score combining CRP with a measure of triglyceride-related insulin resistance as the single most informative marker across all three populations. Across NHANES, the UK Biobank, and a large Chinese longitudinal study, higher values of this CRP-inclusive index were consistently associated with advanced CKM stage and predicted future disease progression. The consistency across populations strengthens the biological story: CRP is not just correlating with CKM by chance. It is tracking something real and reproducible about the metabolic-inflammatory process that drives the syndrome.

A further 2026 analysis in the Anatolian Journal of Cardiology examined a combined index of residual cholesterol and CRP in NHANES and Chinese cohorts, again finding robust associations with CKM risk at even early disease stages. Each one-unit increase in the combined index was associated with a 4 percent higher CKM risk in the US sample and a 3 percent higher risk in the Chinese sample, with effects present across most demographic subgroups (Zhang et al., 2026). The repeated appearance of CRP in these composite markers underlines a consistent pattern: among the many biomarkers researchers have tested, CRP keeps showing up as a sensitive and broadly applicable signal of CKM-related metabolic dysfunction.

What This Means for Everyday Wellness Monitoring

The practical implication of detecting inflammation at CKM stage 1, rather than at later stages, is a wider and earlier window for lifestyle intervention. Stages 1 and 2 of CKM syndrome respond well to the kinds of changes that do not require prescription medication: reducing caloric surplus, increasing physical activity, improving sleep, and shifting dietary patterns toward whole foods and away from ultra-processed options. These interventions lower hs-CRP, reduce visceral fat, and improve insulin sensitivity. If elevated CRP reliably flags the early stage at which these interventions are most powerful, then tracking CRP over time becomes a more meaningful wellness tool than it might have seemed when CRP was thought to rise only once disease was established.

Interpreting a single CRP value has well-known limitations. Acute infections, minor injuries, and even intense exercise can temporarily push CRP up. This is why the most useful information often comes from tracking trends rather than interpreting a one-time result. A sustained hs-CRP above 2 mg/L in the absence of obvious acute illness is a different story from a transient spike. Watching the direction of change over weeks and months, while making lifestyle adjustments, gives a more complete picture than any single number.

It is also worth being clear about what CRP does not tell you on its own. An elevated reading does not diagnose any specific condition, and a normal reading does not guarantee absence of cardiovascular risk. CRP is a general inflammatory signal, and its causes are many. Persistent elevations are worth discussing with a healthcare provider, who can interpret the result alongside other clinical information. The value of tracking it as a wellness data point lies in the longitudinal pattern, not in any single snapshot.

The Broader Picture: Inflammation as an Early Driver, Not a Late Consequence

Perhaps the most significant conceptual shift in the new research is the temporal one. For much of the history of cardiovascular medicine, inflammation was understood as something that happened because of disease: plaques became inflamed, failing kidneys generated inflammatory signaling, diabetic tissues triggered immune responses. The CKM syndrome framework was already beginning to challenge this view by emphasizing the metabolic roots of cardiovascular disease. Now, research showing that hs-CRP rises sharply at the earliest identifiable stage, before any organ damage is documented, pushes the inflammatory story even further back in the timeline.

This does not mean inflammation alone causes CKM syndrome. The relationship is almost certainly bidirectional and self-reinforcing: excess adiposity drives inflammation, inflammation drives insulin resistance, insulin resistance worsens adiposity, and so on. But recognizing that the inflammatory signal is measurable early means that CRP is not just a lagging indicator of what has already happened. At least in part, it appears to track a process that is actively unfolding and potentially interruptible.

For the growing number of people who want to take a proactive approach to their long-term health, this is a genuinely useful piece of information. The CKM syndrome framework matters precisely because it describes a progression that starts with common, modifiable risk factors, many of which are addressed by the same lifestyle changes that happen to lower CRP. The convergence of those two facts, that CRP rises early and that early-stage CKM is the most responsive to lifestyle change, makes inflammation monitoring a reasonable part of a forward-looking wellness strategy. Any sustained elevations should be shared with a healthcare provider, who can assess the full clinical picture and determine whether additional evaluation or intervention is warranted.

Sources

• Corsi et al. High-sensitivity C-reactive protein across the cardiovascular-kidney-metabolic syndrome spectrum: a nationally representative, survey-weighted analysis of US adults. European Journal of Preventive Cardiology, 2026. academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwag476/8790362
• Ndumele CE et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation, 2023. pubmed.ncbi.nlm.nih.gov/37807924
• Zeng Y et al. Integrative Inflammation-Metabolism Indicator for Cardiovascular-Kidney-Metabolic Syndrome: Evaluating the C-Reactive Protein-Triglyceride Glucose Index for Risk Stratification and Progression Across Three National Cohorts. Mediators of Inflammation, 2026. pubmed.ncbi.nlm.nih.gov/42517347
• Zhang M et al. Residual Cholesterol Inflammatory Index: A Predictor of Cardiovascular-Kidney-Metabolic Syndrome; Insights from NHANES and CHARLS Cohorts. Anatolian Journal of Cardiology, 2026. pubmed.ncbi.nlm.nih.gov/42411663
• News coverage: Inflammation is already elevated at the earliest stage of cardiovascular-kidney-metabolic syndrome. News-Medical.net, October 14, 2026. news-medical.net

Frequently Asked Questions

What is cardiovascular-kidney-metabolic syndrome?

Cardiovascular-kidney-metabolic (CKM) syndrome is a framework introduced by the American Heart Association in 2023 to describe the overlapping relationship between metabolic risk factors such as obesity and impaired blood glucose, chronic kidney disease, and cardiovascular disease. It is staged from 0 (no risk factors) through 4 (established cardiovascular disease with kidney or metabolic comorbidities), providing clinicians with a unified way to assess and prevent disease across interconnected organ systems.

Why does CRP rise at the earliest stage of CKM syndrome?

Excess visceral fat, one of the defining features of CKM stage 1, secretes pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha. These signals reach the liver and stimulate CRP production. This means inflammation can be detectable in the blood even before any kidney or heart disease has developed, reflecting the metabolic disruptions that drive the early stage of the syndrome.

What does a CRP level above 2 mg/L mean?

An hs-CRP above 2 mg/L is commonly associated with increased cardiovascular risk in the clinical literature. It suggests ongoing low-grade systemic inflammation. A single elevated reading should be interpreted cautiously, since infection, minor injury, or exercise can temporarily raise CRP. A sustained elevation across multiple measurements is more clinically meaningful and worth discussing with a healthcare provider to assess the full picture.

Can lifestyle changes lower CRP in early CKM syndrome?

Yes, research consistently shows that the lifestyle interventions most effective for early-stage CKM, including weight loss, increased physical activity, improved sleep, and a diet rich in whole foods and low in ultra-processed options, also lower hs-CRP. Tracking CRP over time can provide feedback on whether those changes are reducing systemic inflammation, though persistent elevations should always be evaluated by a healthcare provider.